Table 3.
Comparison between demographic and clinical data in nonvalvular atrial fibrillation patients on oral anticoagulation and non-anticoagulated in both groups and respectively between those anticoagulated with AVK or NOAC in group 2.
| Parameter | Group 1 (n = 286) | p | Group 2 (n = 433) | p | Group 2 ACO (n = 377) | ||||
|---|---|---|---|---|---|---|---|---|---|
| ACO (n = 199) | nonACO (n = 87) |
ACO (n = 377) | nonACO (n = 56) |
AVK (n = 167) |
NOAC (n = 210) | p | |||
| Age (years) | 71.6 ± 9.9 | 75.6 ± 8.7 | 0.001 | 73.7 ± 10.2 | 74.5 ± 11.4 | 0.5768 | 72.5 ± 10 | 74.7 ± 10.3 | 0.03 |
| Sex—male (n, %) | 106 (53.3) | 44 (49.4) | 0.5496 | 171 (45.4) | 22 (39.3) | 0.3936 | 74 (44.3) | 97 (46.2) | 0.71 |
| Myocardial infarction (n, %) | 30 (15.4) | 11 (12.6) | 0.5464 | 48 (12.8) | 9 (16.1) | 0.4953 | 16 (9.6) | 32 (15.2) | 0.10 |
| Congestive heart failure (n, %) | 147 (73.9) | 66 (75.9) | 0.7221 | 282 (75.2) | 35 (62.5) | 0.0444 | 132 (79) | 150 (71.4) | 0.08 |
| PAD (n, %) | 16 (8.04) | 6 (6.9) | 0.7384 | 42 (11.2) | 11 (19.6) | 0.0713 | 24 (14.3) | 18 (8.5) | 0.07 |
| ASC (n, %) | 39 (19.7) | 27 (31) | 0.0366 | 135 (35.8) | 21 (37.5) | 0.8057 | 61 (36.5) | 74 (35.2) | 0.79 |
| Dementia (n, %) | 26 (13.1) | 17 (19.5) | 0.1586 | 13 (3.5) | 10 (17.9) | <0.0001 | 3 (1.7) | 10 (4.7) | 0.11 |
| COPD (n, %) | 48 (24.1) | 19 (21.8) | 0.6751 | 64 (16.7) | 7 (12.5) | 0.3985 | 32 (19.1) | 32 (15.2) | 0.31 |
| Uncomplicated DM (n, %) | 40 (20.1) | 12 (13.8) | 0.2032 | 61 (16.2) | 17 (30.4) | 0.0103 | 28 (16.7) | 33 (15.7) | 0.79 |
| Complicated DM (n, %) | 16 (8) | 6 (6.9) | 0.7574 | 53 (14.1) | 10 (17.9) | 0.4568 | 30 (17.9) | 23 (10.9) | 0.05 |
| Moderate-severe CKD (n, %) | 49 (24.9) | 32 (37.2) | 0.0347 | 41 (10.9) | 7 (12.5) | 0.7229 | 22 (13.1) | 19 (9) | 0.19 |
| Hemiplegia (n, %) | 4 (2) | 2 (2.3) | 1 | 5 (1.3) | 2 (3.6) | 0.2256 | 3 (1.7) | 2 (0.9) | 0.47 |
| Leukemia (n, %) | 0 (0) | 3 (3.5) | 0.0277 | 3 (0.8) | 1 (1.8) | 0.4265 | 1 (0.5) | 2 (0.9) | 0.58 |
| Lymphoma (n, %) | 0 (0) | 2 (2.3) | 0.0915 | 2 (0.5) | 0 (0) | 1 | 1 (0.5) | 1 (0.4) | 0.69 |
| Neoplasm (n, %) | 26 (13.1) | 21 (24.1) | 0.0211 | 39 (10.3) | 9 (16.1) | 0.2027 | 15 (8.9) | 24 (11.4) | 0.43 |
| Metastasis (n, %) | 3 (1.5) | 8 (9.2) | 0.0041 | 15 (3.9) | 0 (0) | 0.2357 | 6 (3.5) | 9 (4.2) | 0.73 |
| Mild liver disease (n, %) | 70 (35.4) | 32 (36.8) | 0.8168 | 24 (6.4) | 6 (10.7) | 0.2565 | 12 (7.1) | 12 (5.7) | 0.55 |
| Severe liver disease (n, %) | 5 (2.5) | 6 (6.9) | 0.0968 | 11 (2.9) | 2 (3.6) | 0.7945 | 6 (3.5) | 5 (2.3) | 0.48 |
| AIDS (n, %) | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 | 0 (0) | 0 (0) | 1 |
| HTN (n, %) | 151 (79.1) | 65 (75.6) | 0.5182 | 334 (88.2) | 47 (85.4) | 0.5002 | 146 (87.4) | 188 (89.5) | 0.52 |
| Anemia (n, %) | 35 (21.9) | 34 (49.3) | <0.0001 | 123 (32.6) | 17 (30.4) | 0.7348 | 57 (34.1) | 66 (31.4) | 0.57 |
| Creatinine (mg/dL) | 1 ± 0.5 | 1.2 ± 0.6 | 0.0197 | 1.1 ± 0.4 | 1.4 ± 0.8 | 0.1737 | 1.16 ± 0.53 | 1.08 ± 0.3 | 0.44 |
| ClCr by MDRD equation (mL/min/1.73 m2) | 63 ± 20.1 | 55.5 ± 19.8 | 0.0086 | 61.7 ± 20.1 | 55.8 ± 24.8 | 0.0982 | 60.6± 20.9 | 62.5 ± 19.4 | 0.36 |
| CHA2 DS2-VASc score | 3.9 ± 1.7 | 4.2 ± 1.5 | 0.1387 | 4.5 ± 1.6 | 4.5 ± 1.9 | 0.8934 | 4.5 ± 1.7 | 4.5 ± 1.5 | 0.97 |
| HAS BLED score | 2.4 ± 1.1 | 2.7 ± 0.9 | 0.0135 | 2.1 ± 1.3 | 2.6 ± 1.4 | 0.0294 | 2.24 ± 1.36 | 1.96 ± 1.22 | 0.06 |
| CCI | 5.7 ± 2.5 | 7.3 ± 3.2 | 0.0002 | 5.3 ± 1.9 | 5.8 ± 2.7 | 0.222 | 5.55 ± 1.92 | 5.17 ± 1.97 | 0.09 |
ACO = oral anticoagulation; AIDS = acquired immunodeficiency syndrome; ASC = cerebrovascular disease; CCI = Charlson comorbidity index; CKD = chronic kidney disease; ClCr = creatinine clearance; COPD = chronic obstructive pulmonary disease; DM = diabetes mellitus; HTN = arterial hypertension; MDRD equation = Modification of Diet in Renal Disease equations; MI = myocardial infarction; PAD = peripheral arterial disease. p-values marked with bold indicate statistically significant p-values.